Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Surgical management of mitral stenosis

Matthew J Sorrentino, MD, FACC
Section Editors
Catherine M Otto, MD
Gabriel S Aldea, MD
Edward Verrier, MD
Deputy Editor
Susan B Yeon, MD, JD, FACC


Mitral stenosis (MS) is a condition characterized by obstruction of blood flow across the mitral valve from the left atrium to the left ventricle. The mechanical obstruction leads to increases in pressure within the left atrium, pulmonary vasculature, and right side of the heart. Most cases of MS are caused by rheumatic heart disease with mitral commisural adhesion, thickened immobile mitral valve leaflets, fibrosis, thickening, shortening, fusion, and calcification of the chordae tendinae. Infrequent causes of MS include mitral annular calcification and congenital MS (including parachute mitral valve). (See "Pathophysiology and natural history of mitral stenosis", section on 'Etiology'.)

If untreated, MS often progresses to significant symptoms (eg, dyspnea and fatigue) and serious complications (eg, pulmonary edema, systemic arterial embolism, pulmonary hypertension, and death). Medical therapy can relieve symptoms but surgical or percutaneous intervention is required to relieve the obstruction to flow. (See "Medical management and indications for intervention for mitral stenosis".)

Surgical approaches to MS are reviewed here. Issues directly related to the indications for intervention and choice of percutaneous mitral balloon valvotomy versus surgery and the medical management of MS are discussed separately. (See "Percutaneous mitral balloon valvotomy for mitral stenosis" and "Medical management and indications for intervention for mitral stenosis".)


Rheumatic MS — When intervention is warranted in patients with rheumatic mitral stenosis (MS), the 2014 American Heart Association/American College of Cardiology (AHA/ACC) guidelines recommend percutaneous mitral balloon valvotomy (PMBV) if the valve morphology is favorable and the patient does not have left atrial thrombus or moderate to severe (3+ to 4+) mitral regurgitation (figure 1 and table 1)[1]. The data supporting this conclusion are presented separately. (See "Percutaneous mitral balloon valvotomy for mitral stenosis", section on 'PMBV versus surgery'.)

However, even with unfavorable anatomy, PMBV may be performed as a palliative procedure if the patient is deemed to be at high risk for surgery and there is no left atrial thrombus or moderate to severe mitral regurgitation. (See "Percutaneous mitral balloon valvotomy for mitral stenosis", section on 'Choice of PMBV'.)


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Aug 2017. | This topic last updated: Mar 20, 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:e57.
  2. Ben Farhat M, Ayari M, Maatouk F, et al. Percutaneous balloon versus surgical closed and open mitral commissurotomy: seven-year follow-up results of a randomized trial. Circulation 1998; 97:245.
  3. Lau KW, Ding ZP, Hung JS. Percutaneous transvenous mitral commissurotomy versus surgical commissurotomy in the treatment of mitral stenosis. Clin Cardiol 1997; 20:99.
  4. Khan MN. The relief of mitral stenosis. An historic step in cardiac surgery. Tex Heart Inst J 1996; 23:258.
  5. Wheeler EO, Wilkins GT, Reynolds TR, et al.. Rheumatic mitral valve disease and tricuspid valve disease. In: The Practice of Cardiology, 2nd ed, Eagle KA, Habe E, DeSanctis R, Austen WG (Eds), Little, Brown, and Company, Boston 1989. p.655.
  6. John S, Bashi VV, Jairaj PS, et al. Closed mitral valvotomy: early results and long-term follow-up of 3724 consecutive patients. Circulation 1983; 68:891.
  7. Pavankumar P, Venugopal P, Kaul U, et al. Closed mitral valvotomy during pregnancy. A 20-year experience. Scand J Thorac Cardiovasc Surg 1988; 22:11.
  8. Reyes VP, Raju BS, Wynne J, et al. Percutaneous balloon valvuloplasty compared with open surgical commissurotomy for mitral stenosis. N Engl J Med 1994; 331:961.
  9. Cohn LH, Allred EN, Cohn LA, et al. Long-term results of open mitral valve reconstruction for mitral stenosis. Am J Cardiol 1985; 55:731.
  10. Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.
  12. Alpert JS, Sabik J, Cosgrove DM III. Mitral valve disease. In: Textbook of Cardiovascular Medicine, Topol EJ (Ed), Lippincott-Raven, Philadelphia 1998. p.503.
  13. García-Fernández MA, Pérez-David E, Quiles J, et al. Role of left atrial appendage obliteration in stroke reduction in patients with mitral valve prosthesis: a transesophageal echocardiographic study. J Am Coll Cardiol 2003; 42:1253.
  14. Appelbaum A, Kouchoukos NT, Blackstone EH, Kirklin JW. Early risks of open heart surgery for mitral valve disease. Am J Cardiol 1976; 37:201.
  15. Feldman T. Rheumatic Mitral Stenosis. Curr Treat Options Cardiovasc Med 2000; 2:93.
  16. Li M, Dumesnil JG, Mathieu P, Pibarot P. Impact of valve prosthesis-patient mismatch on pulmonary arterial pressure after mitral valve replacement. J Am Coll Cardiol 2005; 45:1034.
  17. Crawford FA Jr. Residual pulmonary artery hypertension after mitral valve replacement: size matters! J Am Coll Cardiol 2005; 45:1041.
  18. Magne J, Mathieu P, Dumesnil JG, et al. Impact of prosthesis-patient mismatch on survival after mitral valve replacement. Circulation 2007; 115:1417.
  19. Bolman RM 3rd. Survival after mitral valve replacement: does the valve type and/or size make a difference? Circulation 2007; 115:1336.